JPMorgan Asset Management Form 8.3 - Pfizer Inc (8244G)
November 24 2015 - 10:20AM
UK Regulatory
TIDMPFZ
RNS Number : 8244G
JPMorgan Asset Management
24 November 2015
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2007 (AS AMENDED)
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing JPMorgan Asset Management
(Note 1)
-------------------------------------- --------------------------
Company dealt in Pfizer Inc.
-------------------------------------- --------------------------
Class of relevant security Ordinary Shares
to which the dealings
being disclosed relate
(Note 2)
-------------------------------------- --------------------------
Date of dealing 23 November 2015
-------------------------------------- --------------------------
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant security dealt in (Note 3)
Long Short
--------------------------------- --------------------- -------------
Number (%) Number (%)
--------------------------------- -------------- ----- ------- ----
(1) Relevant securities 88,576,242 1.44
--------------------------------- -------------- ----- ------- ----
(2) Derivatives (other
than options) 208,388 0.00
--------------------------------- -------------- ----- ------- ----
(3) Options and agreements
to purchase/sell
--------------------------------- -------------- ----- ------- ----
Total 88,784,630 1.44
--------------------------------- -------------- ----- ------- ----
(b) Interests and short positions in relevant securities of the
company, other than the class dealt in (Note 3)
Class of relevant security: Long Short
-------------------------------- ------------- -------------
Number (%) Number (%)
-------------------------------- ------- ---- ------- ----
(1) Relevant securities
-------------------------------- ------- ---- ------- ----
(2) Derivatives (other
than options)
-------------------------------- ------- ---- ------- ----
(3) Options and agreements
to purchase/sell
-------------------------------- ------- ---- ------- ----
Total
-------------------------------- ------- ---- ------- ----
3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant Price per unit
securities (USD)
-------------- ------------------- ---------------
Purchase 72 31.3072 USD
Purchase 2,400 31.4700 USD
Purchase 15,200 31.4839 USD
Purchase 23,400 31.5670 USD
Sale
Sale 237,076 31.1125 USD
Sale 24 31.2728 USD
Sale 134,000 31.3284 USD
Sale 372,900 31.3394 USD
88 31.4528 USD
-------------- ------------------- ---------------
(b) Derivatives transactions (other than options transactions)
Product name, Nature of transaction Number of relevant Price per unit
e.g. CFD (Note 6) securities (Note (Note 5)
7)
-------------- ---------------------- ------------------- ---------------
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, Writing, Number of Exercise Type, Expiry Option
e.g. call selling, securities price e.g. American, date money
option purchasing, to which European paid/received
varying the option etc. per unit
etc. relates (Note (Note 5)
7)
-------------- ------------- --------------- --------- ---------------- ------- ---------------
(ii) Exercising
Product name, e.g. Number of securities Exercise price per
call option unit (Note 5)
------------------- --------------------- -------------------
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction Details Price per unit (if
(Note 8) applicable) (Note
5)
---------------------- -------- -------------------
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating
to the voting rights of any relevant securities under
any option referred to on this form or relating to the
voting rights or future acquisition or disposal of any
relevant securities to which any derivative referred
to on this form is referenced. If none, this should
be stated.
-------------------------------------------------------------
Is a Supplemental Form 8 attached? NO
(Note 9)
Date of disclosure 24 November 2015
--------------------------------------------- ----------------------
Contact name Evangelos Galiatsatos
--------------------------------------------- ----------------------
Telephone number 0207 742 6148
--------------------------------------------- ----------------------
If a connected EFM, name of offeree/offeror N/A
with which connected
--------------------------------------------- ----------------------
If a connected EFM, state nature N/A
of connection (Note 10)
--------------------------------------------- ----------------------
The Notes on Form 8.3 can be viewed on the Panel's website at
www.irishtakeoverpanel.ie.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ISEBIBATMBBTBPA
(END) Dow Jones Newswires
November 24, 2015 10:20 ET (15:20 GMT)
Pfizer (LSE:PFZ)
Historical Stock Chart
From Oct 2024 to Nov 2024
Pfizer (LSE:PFZ)
Historical Stock Chart
From Nov 2023 to Nov 2024
